MCID: NRF003
MIFTS: 42

Neurofibrosarcoma

Categories: Rare diseases, Neuronal diseases, Cancer diseases

Aliases & Classifications for Neurofibrosarcoma

MalaCards integrated aliases for Neurofibrosarcoma:

Name: Neurofibrosarcoma 12 72 49 28 13 51 41 14 69
Malignant Peripheral Nerve Sheath Tumor 69
Neurosarcoma [obs] 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3512
MeSH 41 D018319
SNOMED-CT 64 19897006 404037002
UMLS 69 C0206729

Summaries for Neurofibrosarcoma

MalaCards based summary : Neurofibrosarcoma, also known as malignant peripheral nerve sheath tumor, is related to malignant peripheral nerve sheath tumor and neurofibromatosis, type iv, of riccardi. An important gene associated with Neurofibrosarcoma is MXI1 (MAX Interactor 1, Dimerization Protein), and among its related pathways/superpathways is Glioblastoma Multiforme. The drugs Doxorubicin and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include bone, testis and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 72 A malignant peripheral nerve sheath tumor (MPNST) (also known as \"malignant schwannoma\",... more...

Related Diseases for Neurofibrosarcoma

Diseases related to Neurofibrosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Related Disease Score Top Affiliating Genes
1 malignant peripheral nerve sheath tumor 31.8 MXI1 NF1 NF2
2 neurofibromatosis, type iv, of riccardi 30.3 NF1 NF2
3 neurofibroma 30.1 NF1 NF2
4 childhood malignant schwannoma 10.9
5 adult malignant schwannoma 10.9
6 neurofibromatosis, familial spinal 10.2 NF1 NF2
7 plexiform schwannoma 10.2 NF1 NF2
8 immature cataract 10.2 NF1 NF2
9 plexiform neurofibroma 10.2 NF1 NF2
10 atypical neurofibroma 10.2 NF1 NF2
11 amyloid tumor 10.2 NF1 NF2
12 spinal canal and spinal cord meningioma 10.2 NF1 NF2
13 neurilemmomatosis 10.2 NF1 NF2
14 spinal meningioma 10.2 NF1 NF2
15 optic nerve neoplasm 10.2 NF1 NF2
16 cellular schwannoma 10.1 NF1 NF2
17 spinal cord ependymoma 10.1 NF1 NF2
18 neurofibromatosis, type ii 10.1 NF1 NF2
19 neurilemmoma 10.1 NF1 NF2
20 sarcoma 10.1
21 organ system benign neoplasm 10.1 NF1 NF2
22 ependymoma 10.0 NF2 TP73
23 peripheral nervous system neoplasm 10.0 NF1 NF2
24 nervous system cancer 10.0 NF1 NF2
25 autosomal genetic disease 9.9 NF1 NF2
26 elephantiasis 9.9 INSRR NF1
27 neurofibromatosis, type i 9.8
28 mediastinitis 9.8
29 hypoglycemia 9.8
30 meningioma, familial 9.8 NF1 NF2 TP73
31 autosomal dominant disease 9.7 NF1 NF2
32 spondyloarthropathy 1 9.7
33 lipomatosis, multiple 9.7
34 ovarian cancer 9.7
35 pheochromocytoma 9.7
36 lymphoma, hodgkin, classic 9.7
37 myasthenia gravis 9.7
38 thymoma, familial 9.7
39 wilms tumor 5 9.7
40 wilms tumor 6 9.7
41 angiosarcoma 9.7
42 lymphoma 9.7
43 inflammatory spondylopathy 9.7
44 graves' disease 9.7
45 hyperinsulinemic hypoglycemia 9.7
46 prostatitis 9.7
47 leiomyosarcoma 9.7
48 neuroma 9.7
49 cervicitis 9.7
50 thymoma 9.7

Graphical network of the top 20 diseases related to Neurofibrosarcoma:



Diseases related to Neurofibrosarcoma

Symptoms & Phenotypes for Neurofibrosarcoma

GenomeRNAi Phenotypes related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.32 DCK
2 Decreased viability GR00221-A-1 9.32 DCK INSRR NF1
3 Decreased viability GR00221-A-2 9.32 DCK NF1
4 Decreased viability GR00221-A-4 9.32 DCK NF1
5 Decreased viability GR00240-S-1 9.32 DCK
6 Decreased viability GR00301-A 9.32 INSRR

MGI Mouse Phenotypes related to Neurofibrosarcoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.65 DCK MXI1 NF1 NF2 TP73
2 immune system MP:0005387 9.55 DCK MXI1 NF1 NF2 TP73
3 neoplasm MP:0002006 9.26 MXI1 NF1 NF2 TP73
4 renal/urinary system MP:0005367 8.92 INSRR MXI1 NF1 NF2

Drugs & Therapeutics for Neurofibrosarcoma

Drugs for Neurofibrosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
2
Ifosfamide Approved Phase 3,Phase 2,Phase 1 3778-73-2 3690
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1 51-75-2 4033
4
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
5
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
6
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
7
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
9
Dactinomycin Approved, Investigational Phase 3 50-76-0 457193 2019
10
Epirubicin Approved Phase 3 56420-45-2 41867
11
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
12
Trabectedin Approved, Investigational Phase 3,Phase 2 114899-77-3 108150
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Cyproheptadine Approved Phase 3 129-03-3 2913
15
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
16
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
17
Docetaxel Approved May 1996, Investigational Phase 3,Phase 1,Phase 2 114977-28-5 148124 9877265
18 Alkylating Agents Phase 3,Phase 2,Phase 1
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Isophosphamide mustard Phase 3,Phase 2,Phase 1 0
22 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2
24 Etoposide phosphate Phase 3,Phase 2
25 Anti-Infective Agents Phase 3,Phase 1,Phase 2
26 Antimitotic Agents Phase 3,Phase 2,Phase 1
27 Antirheumatic Agents Phase 3,Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Nucleic Acid Synthesis Inhibitors Phase 3
30 Imatinib Mesylate Phase 2, Phase 3,Phase 1 123596
31 Protein Kinase Inhibitors Phase 2, Phase 3,Phase 1
32 Antimetabolites Phase 3,Phase 2,Phase 1
33 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
34 Antiviral Agents Phase 3,Phase 2,Phase 1
35 Anti-Allergic Agents Phase 3
36 Antipruritics Phase 3
37 Dermatologic Agents Phase 3
38 Gastrointestinal Agents Phase 3
39 Histamine Antagonists Phase 3
40 Histamine H1 Antagonists Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Neurotransmitter Agents Phase 3
43
Serotonin Phase 3 50-67-9 5202
44 Serotonin Agents Phase 3
45 Serotonin Antagonists Phase 3
46
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
47
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
48
Romidepsin Approved, Investigational Phase 2 128517-07-7 5352062
49
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
50
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177

Interventional clinical trials:

(show top 50) (show all 72)

# Name Status NCT ID Phase Drugs
1 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
2 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
3 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
4 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
5 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
6 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
7 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
8 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
10 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
11 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
12 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
13 Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
14 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
15 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
16 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
17 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
18 S0330 Erlotinib in Treating Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor Completed NCT00068367 Phase 2 erlotinib hydrochloride
19 Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
20 Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
21 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2 sorafenib tosylate
22 Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma Completed NCT00112463 Phase 2 romidepsin
23 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
24 Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
25 Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Completed NCT00154388 Phase 2 Imatinib mesylate
26 BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Completed NCT00526149 Phase 2 BI 2536
27 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
28 Ecteinascidin 743 in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00003939 Phase 2 trabectedin
29 STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
30 Brostallicin in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00041249 Phase 2 brostallicin
31 Exatecan Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma Completed NCT00041236 Phase 2 exatecan mesylate
32 Perifosine in Treating Patients With Metastatic or Locally Advanced Soft Tissue Sarcoma Completed NCT00053794 Phase 2 perifosine
33 Imatinib Mesylate in Treating Patients With Advanced Soft Tissue Sarcoma or Bone Sarcoma Completed NCT00031915 Phase 2 imatinib mesylate
34 Safety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent Sarcoma Completed NCT00949325 Phase 1, Phase 2 temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)
35 A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Recruiting NCT02691026 Phase 2 Pembrolizumab
36 PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
37 Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02986919 Phase 2 CPI-0610
38 A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma Recruiting NCT02601950 Phase 2 Tazemetostat
39 Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma Recruiting NCT02601209 Phase 1, Phase 2 Pazopanib Hydrochloride;Sapanisertib
40 Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers Recruiting NCT03215511 Phase 1, Phase 2 LOXO-195
41 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
42 Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin;Olaratumab
43 Gemcitabine Hydrochloride With or Without Pazopanib Hydrochloride in Treating Patients With Refractory Soft Tissue Sarcoma Recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
44 Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma Recruiting NCT01883518 Phase 1, Phase 2
45 SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors Active, not recruiting NCT01661283 Phase 2 everolimus;bevacizumab
46 SARC023: Ganetespib and Sirolimos in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) Active, not recruiting NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
47 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
48 Trial of Dasatinib in Advanced Sarcomas Active, not recruiting NCT00464620 Phase 2 Dasatinib
49 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Active, not recruiting NCT01614795 Phase 2 temsirolimus
50 SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the Dual mTOR Kinase Inhibitor Vistusertib (AZD2014) for Patients With Malignant Peripheral Nerve Sheath Tumors Not yet recruiting NCT03433183 Phase 2 Selumetinib;Vistusertib

Search NIH Clinical Center for Neurofibrosarcoma

Cochrane evidence based reviews: neurofibrosarcoma

Genetic Tests for Neurofibrosarcoma

Genetic tests related to Neurofibrosarcoma:

# Genetic test Affiliating Genes
1 Neurofibrosarcoma 28

Anatomical Context for Neurofibrosarcoma

MalaCards organs/tissues related to Neurofibrosarcoma:

38
Bone, Testis, Lung, Breast, Small Intestine, Tongue, Prostate

Publications for Neurofibrosarcoma

Articles related to Neurofibrosarcoma:

(show top 50) (show all 127)
# Title Authors Year
1
A case report of cervical neurofibrosarcoma: Clinical presentation, treatment and outcome. ( 29253810 )
2018
2
Hemisacrectomy with preservation of the contralateral sacral nerve roots and sacroiliac joint for pelvic neurofibrosarcoma in a 7-year-old child: case report with 2-year follow-up. ( 27689246 )
2017
3
Seriously saRComa: Neurofibrosarcoma. ( 27789422 )
2016
4
Neurofibrosarcoma of the Subglottis-A Rare Case Report. ( 26405416 )
2015
5
Neurofibrosarcoma of the lumbar spine with a misleading onset. ( 25542749 )
2015
6
Neurofibrosarcoma of the gallbladder: a case report. ( 23938157 )
2013
7
Molecular characteristics and pathogenicity of an avian leukosis virus isolated from avian neurofibrosarcoma. ( 22545526 )
2012
8
Endocervical fibroblastic malignant peripheral nerve sheath tumor (neurofibrosarcoma): report of a novel entity possibly related to endocervical CD34 fibrocytes. ( 21317712 )
2011
9
Rare association of Hodgkin lymphoma, Graves' disease and myasthenia gravis complicated by post-radiation neurofibrosarcoma: coincidence or genetic susceptibility? ( 19381762 )
2009
10
Gross and histopathological characteristics of two lipomas and a neurofibrosarcoma detected in aquacultured southern bluefin tuna, Thunnus maccoyii (Castelnau), in South Australia. ( 18353015 )
2008
11
A case of fibroblastic low-grade malignant peripheral nerve sheath tumor--a true neurofibrosarcoma. ( 17963184 )
2007
12
The genetic predisposition to and histogenesis of neurofibromas and neurofibrosarcoma in neurofibromatosis type 1. ( 17613220 )
2007
13
Total sacrectomy and reconstruction with structural allografts for neurofibrosarcoma of the sacrum. A case report. ( 15805218 )
2005
14
Neurofibrosarcoma - complicating neurofibromatosis-I: case report and review of relevant literature. ( 16160727 )
2005
15
Pediatric neurofibrosarcoma. ( 12632346 )
2003
16
Aberrant CpG island methylation in neurofibromas and neurofibrosarcomas. ( 12883734 )
2003
17
A study of the influence of newly synthesized acyclonucleosides and 1,2,3,4-tetrahydroisoquinoline derivatives on deoxythymidine and deoxycytidine kinase activities in human neurofibrosarcoma and ovarian cancer. ( 14740004 )
2003
18
Retroperitoneal neurofibrosarcoma in a patient with neurofibromatosis. 2: A case report and review of the literature. ( 14692188 )
2003
19
Metastatic spinal neurofibrosarcoma. ( 11880913 )
2002
20
Association of soft tissue sarcomas other than neurofibrosarcoma with neurofibromatosis. ( 12555884 )
2002
21
Neurofibrosarcoma in the nasal cavity. ( 23119773 )
2001
22
Periocular neurofibrosarcoma in a horse. ( 11906658 )
2001
23
Malignant spinal neurofibrosarcoma. ( 10752112 )
2000
24
Orbital neurofibrosarcoma in a dog. ( 11397256 )
1999
25
Posterior mediastinal neurofibrosarcoma in a patient with von Recklinghausen's disease. ( 10413818 )
1999
26
Cerebral air emboli in a child with neurofibrosarcoma. ( 10227545 )
1999
27
Mxi1 mutations in human neurofibrosarcomas. ( 10470286 )
1999
28
Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. ( 9766530 )
1998
29
Case 3: Neurofibromatosis I with metastases from a thigh neurofibrosarcoma. ( 9725330 )
1998
30
Removal of a thymoma via median sternotomy in a rabbit with recurrent appendicular neurofibrosarcoma. ( 9787381 )
1998
31
Case report: isolated neurofibrosarcoma of the liver: US, CT and MR findings. ( 9112953 )
1997
32
Paraneoplastic opsoclonus-myoclonus syndrome and neurofibrosarcoma. ( 8864716 )
1996
33
Metastatic multicentric neurofibrosarcoma of the lumbosacral plexus in a cow. ( 8740716 )
1996
34
Bone scans in neurofibromatosis: neurofibroma, plexiform neuroma and neurofibrosarcoma. ( 8917174 )
1996
35
Clonal karyotypic evolution in a pediatric neurofibrosarcoma. ( 7621409 )
1995
36
Orbital neurofibrosarcoma: a case report. ( 8919474 )
1995
37
Neurofibrosarcoma of the duodenum. ( 7589610 )
1995
38
Involvement of 22q12 in a neurofibrosarcoma in neurofibromatosis type 1. ( 8467471 )
1993
39
Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. ( 8499945 )
1993
40
Neurofibrosarcoma of the intrathoracic vagus nerve. Case report. ( 8211005 )
1993
41
Treatment of a large high-grade neurofibrosarcoma with concomitant vinblastine, doxorubicin, and radiotherapy. ( 1435843 )
1992
42
Oral neurofibrosarcoma associated with neurofibromatosis type I. ( 1923446 )
1991
43
Bronchial neurofibrosarcoma. ( 1929641 )
1991
44
Pigmented neurofibrosarcoma mimicking a large haemangioma. ( 1806329 )
1991
45
A case of neurofibrosarcoma associated with neurofibromatosis--ganglioside analysis. ( 1806326 )
1991
46
Immunohistochemical localization of type I, III, IV, V, and VI collagens and laminin in neurofibroma and neurofibrosarcoma. ( 1928621 )
1991
47
von Recklinghausen's neurofibromatosis with neurofibrosarcoma. ( 1900842 )
1991
48
Pigmented neurofibrosarcoma mimicking a large haemangioma. ( 2279344 )
1990
49
Neurofibrosarcoma of skin and subcutaneous tissues. ( 1689440 )
1990
50
Chromosomes 17 and 22 involved in marker formation in neurofibrosarcoma in von Recklinghausen disease. A cytogenetic and in situ hybridization study. ( 2118474 )
1990

Variations for Neurofibrosarcoma

ClinVar genetic disease variations for Neurofibrosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MXI1 NM_130439.3(MXI1): c.362C> T (p.Ala121Val) single nucleotide variant Pathogenic rs137852604 GRCh37 Chromosome 10, 111988034: 111988034

Expression for Neurofibrosarcoma

Search GEO for disease gene expression data for Neurofibrosarcoma.

Pathways for Neurofibrosarcoma

Pathways related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.67 NF1 NF2

GO Terms for Neurofibrosarcoma

Biological processes related to Neurofibrosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.33 MXI1 NF1 NF2
2 negative regulation of cell migration GO:0030336 9.32 NF1 NF2
3 negative regulation of protein kinase activity GO:0006469 9.26 NF1 NF2
4 negative regulation of MAPK cascade GO:0043409 8.96 NF1 NF2
5 negative regulation of cell-matrix adhesion GO:0001953 8.62 NF1 NF2

Sources for Neurofibrosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....